TATE and Pembrolizumab (MK3475) in mCRC and NSCLC
A phase 2 trial of Pembrolizumab, Trifluridine/tipiracil, Regorafenib in colorectal cancer, run by Teclison Ltd., now recruiting.
Overview
TATE and Pembrolizumab (MK3475) in mCRC and NSCLC is a phase 2 interventional study registered as NCT04701476 by Teclison Ltd., with 110 participants planned, started 2021-05-20 and due to reach its primary completion in 2027-03-31. Interventions recorded: TATE and pembrolizumab, TAS-102 pill, Regorafenib Pill. Conditions listed: Colorectal Cancer; Lung Cancer. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialInjection of SHR-A1811 Versus Physician Choiced Treatment in Patients With Advanced Colorectal Cancer Who Had Failed to Respond to Oxaliplatin, 5-fu,
Shares Trifluridine/tipiracil, Regorafenib, Colorectal cancer.
- TrialA Randomized Phase 2 Trial of Fruquintinib and TAS-102 as Compared to Fruquintinib in Patients With Refractory Advanced/Metastatic Colorectal Cancer
Shares Trifluridine/tipiracil, Colorectal cancer.
- TrialA Phase Ib/III Study of Suvemcitug Plus FTD/TPI in Participants With Refractory Metastatic Colorectal Cancer
Shares Trifluridine/tipiracil, Colorectal cancer.
- TrialNelmastobart in Combination With Trifluridine/ Tipiracil and Bevacizumab in Metastatic/ Recurrent Colorectal Cancer
Shares Trifluridine/tipiracil, Colorectal cancer.
- TrialSUNLIGHT
Shares Trifluridine/tipiracil, Colorectal cancer.
- TrialAn Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of Ruxolitinib
Shares Regorafenib, Colorectal cancer.
- TrialStudy of XL092 + Atezolizumab vs Regorafenib in Participants With Metastatic Colorectal Cancer
Shares Regorafenib, Colorectal cancer.
- TrialADG126 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors
Shares Trifluridine/tipiracil, Pembrolizumab.